TwitterLinkedin

Contact Us

  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Our Milestones
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Development Strategy and Gap Analysis
            • Integrated Product Development
            • Market Access Strategy
            • Non-clinical Development Concept
              and Study Design
            • Scientific Advice
            • Scientific Due Diligence
            • Statistical Services
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Orphan Drug Designation
            • Pediatric Investigation Plan (PIP)
            • Scientific Advice
            • Statistical Services
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • IMP Management
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
            • Vendor Management and Oversight
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistical Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Environmental Risk Assessment
            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • Audit and CAPA Management
            • EU QPPV / National QPPV
            • ICSR Management
            • Literature Screening
            • Pharmacovigilance Systems
            • Safety Writing (PSUR, RMP)
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • Good Distribution Practice (GDP) Compliance
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Vendor Audit
            • Vendor Management and Oversight
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
            • Medical Information
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • Consulting
            • Consumer Healthcare
            • Generics
            • Herbal Medicines
            • Medicinal Products
            • MedTech Services
            • Pharmaceutical
            • Veterinary Drugs
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • Brexit
            • COVID-19 Support
            • Drug Re-purposing / Value-added Medicines
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Statistical Services
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Career Opportunities
  • Training
Home > News & Events > Ireland > EU Advice on Fluroquinolone Antibiotics – Use and Reactions

EU Advice on Fluroquinolone Antibiotics – Use and Reactions

EMA – recently published guidance:

The European Medical Agency (EMA) has recently published guidance documentation to support organisations prepare for the obligations arising from the new EU regulations on medical devices and in-vitro diagnostics. The medical devices regulation (Regulation (EU) 2017/745) and the in-vitro diagnostics regulation (Regulation (EU) 2017/746) have replaced the three existing directives (93/42/EEC, 98/79/EC and 90/385/EEC) for medical devices. The new regulations came into effect on the 25th May 2017, however, a transition period has been given to allow manufacturers, notified bodies and authorities to adapt to the changes. Therefore, the new regulations will come into full effect on 26 May 2020 for medical devices (Regulation (EU) 2017/745) and 26 May 2022 for in-vitro diagnostics (Regulation (EU) 2017/746).

The Health Products Regulatory Authority (HPRA) have provided a summary of the two new regulations and have highlighted key points of each regulation as follows:

The three key aspects specific to the medical device regulation (MDR) are:

  • More detailed requirements for clinical data for medical devices and its assessment: this provides increased clarity on the requirements for clinical data for medical devices, in particular those of the highest risk, and improves the mechanisms for the assessment of clinical data throughout the lifecycle of a medical device.
  • More specific product requirements: Places greater emphasis on product requirements and the specifications for high risk medical devices.
  • Broader scope: Inclusion of more products which previously have not been regulated as medical devices, such as dermal fillers and colored contact lenses.

The four key points identified in the in-vitro diagnostic (IVD) medical device regulation are:

  • Introduction of a classification system: Classification of IVDs into four different classes based on risk from class A (low) to class D (high).
  • Changes to conformity assessment procedures: IVDs classed as B, C and D will all require assessment and certification by a notified body for medical devices prior to being placed on the market. Significant changes in the regulatory system, because previously IVDs were self-declared devices rather than being assesses by a notified body.
  • Performance evaluation and clinical data requirements: These requirements are defined in greater detail, along with specific requirements in relation to use of clinical data for IVDs and how clinical studies are performed.
  • Changes to requirements for in-house manufacturing of IVDs: The new regulation places requirements on “in-house” IVDs and the healthcare institutions which manufacture them and allows the introduction of additional requirements at national level by individual member states.

There are four key objectives that are common across both regulations:

  • Improved performance of notified bodies for medical devices: Greater clarity in the requirements that a certification organisation must have in order to become a notified body for medical devices.
  • Improved pre-market assessment of high-risk devices: Both regulations provide for additional pre-market scrutiny of the highest risk medical devices by an independent expert panel operating on behalf of the European regulatory system.
  • Enhanced provisions for market surveillance: Both regulations further define and develop the requirements for the continued surveillance of medical devices on the market by manufacturers and by regulatory authorities.
  • Governance, coordination and cooperation: Both regulations have specific requirements and structures in place, where the national authorities are required to coordinate with each other, in conjunction with the European Commission.

Further details can be found on the HPRA website at the following link: https://www.hpra.ie/homepage/medical-devices/regulatory-information/new-eu-device-regulations

The most recent EMA guidance document (27 February 2019) provides clarification on Article 117 of the medical device regulation (Regulation (EU) 2017/745), which introduces the new requirement for the involvement of the notified body in relation to a medical product with an ‘integral’ medical device’. The Marketing Authorisation (MA) dossier for this category of medical device is expected to include the results of the assessment of conformity for the device.

The guidance provides clarity on a number of questions as follows:

  • What is Article 117 and what does it mean for medicinal products? E.g., requirement for a declaration of conformity or the relevant certificate issued by a notified body.
  • When is a medicinal product considered to form an ‘integral’ product in combination with the administration device?
  • How will the medical devices Regulations and, in particular Article 117, impact new MA applications?
  • When is it required to provide the notified body opinion/EU certificate/declaration of conformity with the Marketing Authorization Application (MAA)?
  • At what stage does the notified body opinion need to be submitted?
  • How does Article 117 of the medical devices Regulation impact currently authorized medicinal products with an integral medical device?
  • Is it necessary to provide a (new or updated) EU certificate/declaration of conformity/notified body opinion if there are changes to the device submitted through a variation/extension?

To read the Questions and Answers document in full, please visit the EMA website on the following link: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-implementation-medical-devices-vitro-diagnostic-medical-devices-regulations-eu/745-eu-2017/746_en.pdf

PharmaLex can support the compliance of your organisation with the new regulations, including the provision of regulatory support, auditing and outsourcing solutions for medical devices. To discuss the range of services that we offer, please connect with us on +353 1 846 4742 or email us at contact@pharmalex.com.

 

.

Related posts
Annex 1
EU GMP Annex 1
25th January 2021
mepharma partnership pharmalex
New Partnership Announcement for MEPHARMA and PharmaLex
21st January 2021
fda webinar
What you need to know to submit Study Data to FDA
19th January 2021
SMARTRISK
SMARTRISK – risk assessment excipient tool
12th January 2021
medical devices digital health era
Medical Devices in the Digital Health Era
10th December 2020
medicinal cannabis
Medicinal Cannabis: The Wonder Substance
1st December 2020
Search
Upcoming Webinars

February 2nd, 2021

Central American Regulation for Drug Products (LATAM)

3 PM CET

February 25th, 2021

What you need to know to submit Study Data to FDA

5PM CET

Upcoming Events

February 8 - 10th, 2021

DIA RSIDM 2021

Visit us at booth Virtual

March 15 - 19th, 2021

DIA Europe 2021

March 22 - 25th, 2021

BIO Europe Spring 2021

Visit us at booth Virtual

June 14 - 17th, 2021

BIO International Convention 2021

June 27 - July 1st, 2021

DIA Annual Meeting 2021

September 22 - 24th, 2021

TOPRA Symposium 2021

Categories
  • All News
  • Webinars
  • Events
Archive
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
Tweets by @PharmaLexGLOBAL
COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We really appreciate your responsiveness and availability during our previous exchanges and it is what we are waiting for from our partner.

    Small Medium Sized Company, UK
    Head of Regulatory Affairs
PharmaLex
©2021 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit Logo

#AskTheExpert #TogetherBEYONDCOVID19





    Select your state:

    .
    You can unsubscribe at any time at data.protection@pharmalex.com

    If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

    #TogetherBEYONDCOVID19

    We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for

      Please DO NOT send us event/conference information.
      We will not respond and these will be deleted immediately.





      Select your state:

      .
      You can unsubscribe at any time at
      data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      Privacy Policy

      This can be specific information about signing up to the newsletter.

      Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.

      Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.

      In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.